Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Depreciation & Amortization (CF) (2020 - 2022)

Atea Pharmaceuticals (AVIR) has 3 years of Depreciation & Amortization (CF) data on record, last reported at $104000.0 in Q4 2022.

  • For Q4 2022, Depreciation & Amortization (CF) rose 1385.71% year-over-year to $104000.0; the TTM value through Dec 2022 reached $260000.0, up 796.55%, while the annual FY2025 figure was $416000.0, 0.0% changed from the prior year.
  • Depreciation & Amortization (CF) reached $104000.0 in Q4 2022 per AVIR's latest filing, down from $106000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $106000.0 in Q3 2022 and bottomed at $4000.0 in Q1 2020.
  • Average Depreciation & Amortization (CF) over 3 years is $25666.7, with a median of $7000.0 recorded in 2021.
  • The widest YoY moves for Depreciation & Amortization (CF): up 1414.29% in 2022, down 0.0% in 2022.
  • A 3-year view of Depreciation & Amortization (CF) shows it stood at $6000.0 in 2020, then grew by 16.67% to $7000.0 in 2021, then skyrocketed by 1385.71% to $104000.0 in 2022.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $104000.0 in Q4 2022, $106000.0 in Q3 2022, and $43000.0 in Q2 2022.